1-(4-Amino-5-chloro-2-methoxyphenyl)-3-(1-(3-((4-methoxyphenyl)sulfonyl)propyl)piperidin-4-yl)propan-1-one

ID: ALA4751840

Chembl Id: CHEMBL4751840

PubChem CID: 162652829

Max Phase: Preclinical

Molecular Formula: C25H33ClN2O5S

Molecular Weight: 509.07

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(S(=O)(=O)CCCN2CCC(CCC(=O)c3cc(Cl)c(N)cc3OC)CC2)cc1

Standard InChI:  InChI=1S/C25H33ClN2O5S/c1-32-19-5-7-20(8-6-19)34(30,31)15-3-12-28-13-10-18(11-14-28)4-9-24(29)21-16-22(26)23(27)17-25(21)33-2/h5-8,16-18H,3-4,9-15,27H2,1-2H3

Standard InChI Key:  JWBCWRINCDHOSR-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4751840

    ---

Associated Targets(Human)

HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

HTR4 Serotonin 4 (5-HT4) receptor (2870 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 509.07Molecular Weight (Monoisotopic): 508.1799AlogP: 4.48#Rotatable Bonds: 11
Polar Surface Area: 98.93Molecular Species: NEUTRALHBA: 7HBD: 1
#RO5 Violations: 1HBA (Lipinski): 7HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 6.68CX LogP: 2.96CX LogD: 2.89
Aromatic Rings: 2Heavy Atoms: 34QED Weighted: 0.35Np Likeness Score: -1.12

References

1. Yahiaoui S,Hamidouche K,Ballandonne C,Davis A,de Oliveira Santos JS,Freret T,Boulouard M,Rochais C,Dallemagne P.  (2016)  Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.,  121  [PMID:27266998] [10.1016/j.ejmech.2016.05.048]

Source